LENZ Therapeutics, Inc./$LENZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Ticker
$LENZ
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
-
ISIN
US52635N1037
Website
LENZ Metrics
BasicAdvanced
$976M
-
-$1.77
-
-
Price and volume
Market cap
$976M
52-week high
$35.95
52-week low
$16.54
Average daily volume
330K
Financial strength
Current ratio
23.09
Quick ratio
22.637
Long term debt to equity
0.351
Total debt to equity
0.616
Profitability
EBITDA (TTM)
-59.364
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-17.75%
Return on equity (TTM)
-24.47%
Valuation
Price to book
4.97
Price to tangible book (TTM)
4.97
Price to free cash flow (TTM)
-17.973
Free cash flow yield (TTM)
-5.56%
Free cash flow per share (TTM)
-193.01%
Growth
Earnings per share change (TTM)
-93.66%
Bulls say / Bears say
LENZ Therapeutics' LNZ100, a treatment for presbyopia, has been accepted by the FDA with a target decision date of August 8, 2025, potentially leading to a significant market opportunity upon approval. (benzinga.com)
The company has entered into exclusive licensing agreements with Lotus Pharmaceutical for Southeast Asia and Laboratoires Théa for Canada, expanding its global reach and potential revenue streams. (globenewswire.com, globenewswire.com)
Analysts have shown confidence in LENZ Therapeutics, with TD Cowen initiating coverage with a 'buy' rating and a $60 price target, indicating strong growth potential. (reuters.com)
LENZ Therapeutics reported a net loss per share of $0.53 in Q1 2025, reflecting ongoing financial challenges as it remains in the pre-commercial stage. (globenewswire.com)
The Bank of New York Mellon Corp reduced its holdings in LENZ Therapeutics by 1.4% in Q4 2024, which may indicate waning confidence among institutional investors. (etfdailynews.com)
Analysts have projected continued losses for LENZ Therapeutics, with estimated earnings per share of ($0.62) in Q2 2025 and ($0.83) in Q4 2025, suggesting ongoing financial strain. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
LENZ News
AllArticlesVideos
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
GlobeNewsWire·5 days ago
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewsWire·2 months ago
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LENZ Therapeutics, Inc. stock?
LENZ Therapeutics, Inc. (LENZ) has a market cap of $976M as of July 12, 2025.
What is the P/E ratio for LENZ Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for LENZ Therapeutics, Inc. (LENZ) stock is 0 as of July 12, 2025.
Does LENZ Therapeutics, Inc. stock pay dividends?
No, LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next LENZ Therapeutics, Inc. dividend payment date?
LENZ Therapeutics, Inc. (LENZ) stock does not pay dividends to its shareholders.
What is the beta indicator for LENZ Therapeutics, Inc.?
LENZ Therapeutics, Inc. (LENZ) does not currently have a Beta indicator.